| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
ML348 (also known as CID 3238952; SID 160654487) is a reversible inhibitor of LYPLA1 (Lysophospholipase 1) with an IC50 value of 210 nM. It exhibits 14-fold selectivity for LYPLA1 over LYPLA2, ML348 is also selective over a panel of ~30 other serine hydrolases. Protein palmitoylation is an essential post-translational modification necessary for trafficking and localization of regulatory proteins that play key roles in cell growth and signaling. Multiple oncogenes, including HRAS and SRC, require palmitoylation for malignant transformation. LYPLA1 has been identified as a candidate protein palmitoyl thioesterase responsible for HRAS depalmitoylation in mammalian cells.
| ln Vitro |
In cultured cells, ML348 (5 μM; 3 hours) selectively inhibits LYPLA1[1].
|
|---|---|
| ln Vivo |
ML348 (50 mg/kg, intraperitoneal, 3 hours) inhibits the LYPLA1 enzymes in the heart, kidney, and lung of mice, demonstrating strong and specific action in vivo[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HEK293T cells, murine T-cells Tested Concentrations: 5 μM Incubation Duration: 3 hrs (hours) Experimental Results: Show potent, selective inhibition of LYPLA1. |
| Animal Protocol |
Animal/Disease Models: C57BL6 male mice (3-4 months)[1]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 hrs (hours) Experimental Results: Potent and selective inhibited LYPLA1 enzymes in heart, kidney and lung in vivo. |
| References |
[1]. Adibekian A et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1). National Center for Biotechnology Information (US); 2010- 2013 Apr 08.
|
| Molecular Formula |
C18H17CLF3N3O3
|
|
|---|---|---|
| Molecular Weight |
415.79
|
|
| CAS # |
899713-86-1
|
|
| Related CAS # |
|
|
| SMILES |
O=C(NC1=CC(C(F)(F)F)=CC=C1Cl)CN2CCN(C(C3=CC=CO3)=O)CC2
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4051 mL | 12.0253 mL | 24.0506 mL | |
| 5 mM | 0.4810 mL | 2.4051 mL | 4.8101 mL | |
| 10 mM | 0.2405 mL | 1.2025 mL | 2.4051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects of APT-1 and APT-2 inhibitors ML348 and ML349 effects on melanoma cells.Oncotarget.2016 Feb 9;7(6):7297-306. |
|---|
|
siRNA knock down of APT-1 and APT-2 in NRAS and BRAF mutant melanoma.Oncotarget.2016 Feb 9;7(6):7297-306. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
